{"nctId":"NCT01313299","briefTitle":"Dysport® Adult Upper Limb Spasticity","startDateStruct":{"date":"2011-08"},"conditions":["Nervous System Disorders"],"count":243,"armGroups":[{"label":"Dysport 500 U","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"Dysport 1000 U","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients - post stroke or brain injury\n* Modified Ashworth Scale ≥ 2\n* Ambulatory patients\n\nExclusion Criteria:\n\n* Previous treatment with botulinum toxin of any type within 4 months prior to study entry for any condition\n* Physiotherapy initiated less than 4 weeks before inclusion\n* Previous surgery, alcohol, phenol in upper limb\n* Neurological/neuromuscular disorders which may interfere with protocol evaluations","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) of Treatment Response","description":"PGA is a 9-point scale used to assess global overall treatment response by the investigator (-4: markedly worse, -3: much worse, -2: worse, -1: slightly worse, 0: no change, +1: slightly improved, +2: improved, +3: much improved and +4: markedly improved).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.0"},{"groupId":"OG001","value":"1.4","spread":"1.1"},{"groupId":"OG002","value":"1.8","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS Score for the Principal Target of Treatment (PTT)","description":"DAS is a 4-point scale used to determine the extent of functional impairment in 4 functional domains (dressing, hygiene, limb position and pain). DAS scale rating: 0=No disability, 1=Mild disability (noticeable but does not interfere significantly with normal activities), 2=Moderate disability (normal activities require increased effort and/or assistance) and 3=Severe disability (normal activities limited).\n\nIf subject chose 'Hygiene' as PTT the score collected will be between 0 and 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.7"},{"groupId":"OG001","value":"-0.7","spread":"0.8"},{"groupId":"OG002","value":"-0.7","spread":"0.7"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG)","description":"MAS scale is used to assess muscle tone using a 6-point scale where: 0=No increase in muscle tone, 1=Slight increase in muscle tone manifested by a catch and release or by minimal resistance at the end of the range of motion (ROM) when the part is flexed or extended, 1±Slight increase in muscle tone manifested by a catch followed by minimal resistance throughout the remainder of the ROM, 2=Marked increase in muscle tone through most of the ROM but affected part easily moved, 3=Considerable increase in muscle tone passive movement difficult or 4=Affected part(s) rigid in flexion or extension. The MAS has been derived for analyses as follows: 0=0 ; 1=1; 1+=2; 2=3; 3=4 and 4=5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.6"},{"groupId":"OG001","value":"-1.2","spread":"1.0"},{"groupId":"OG002","value":"-1.4","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":81},"commonTop":["Nasopharyngitis","Muscular Weakness","Gamma glutamyl transferase increased","Blood triglycerides increased","Arthralgia"]}}}